Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 22,400 shares, a decline of 80.4% from the December 15th total of 114,200 shares. Approximately 5.3% of the company’s stock are short sold. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 0.0 days.

Avalon GloboCare Stock Performance

NASDAQ:ALBT traded down $0.16 during midday trading on Monday, reaching $3.29. 12,786 shares of the stock traded hands, compared to its average volume of 42,255. The business has a 50-day moving average of $3.32 and a two-hundred day moving average of $4.15. Avalon GloboCare has a 12-month low of $2.11 and a 12-month high of $21.60. The stock has a market capitalization of $3.60 million, a PE ratio of -0.16 and a beta of 0.19.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.